Microbicide Trials Network

Ongoing and Planned Studies

MTN-015 - A long-term, observational study that aims to track the nature of HIV progression and treatment response among women who acquired HIV while participating in a MTN “parent study”.  More info…

    

MTN-016 - The Prevention Agent Pregnancy Exposure Registry, also known as EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) seeks to learn whether HIV prevention products containing ARVs can affect a woman’s pregnancy outcome or her baby’s general growth and development.  More Info…

   

MTN-025 (HOPE) – HIV Open Label Prevention Extension – An open-label follow-on trial to ASPIRE in which former ASPIRE participants are offered the opportunity to use the dapivirine ring (there is no placebo) in the context of a study that will gather additional information on the ring’s safety, how women use the ring knowing that it can help reduce their risk of HIV and the relationship between adherence and HIV protection.   More Info…

 

MTN-026 – A Phase I study that will evaluate whether a gel containing dapivirine is safe for use in the rectum. The study will help determine whether further testing on the safety and acceptability of dapivirine gel as a potential rectal microbicide can be conducted in a larger population.   More info...

 

MTN-029/IPM 039 – The first study of its kind involving the dapivirine vaginal ring, MTN-029/IPM 039 will determine whether drug released from the dapivirine ring into the vagina gets absorbed by breastmilk.   More info…

 

MTN-030/IPM 041 – A Phase I trial of a vaginal ring containing the ARV drug dapivirine and the contraceptive hormone levonorgestrel, an important first step toward developing a product for women that could both protect against HIV and prevent unplanned  pregnancy.   More info…

         

MTN-032 – A qualitative study that looks to better understand women’s use of the dapivirine ring in both ASPIRE and HOPE and if and how adherence patterns differ between ASPIRE, a placebo-controlled trial, and the HOPE open-label extension trial in which all women are offered the dapivirine ring, yet may choose not to accept it.   More info…

 

MTN-033 – A Phase I study that will look at the safety and distribution of dapivirine gel when administered rectally like a lubricant (without an applicator) to determine whether enough drug  is delivered in the tissue to feasibly provide HIV protection. 

 

MTN-034/IPM 045 (REACH) – A Phase IIa trial that seeks to understand the HIV prevention needs and preferences of adolescent girls and young women, who are among those at highest risk of HIV in sub-Saharan Africa in a design that will evaluate both the monthly dapivirine ring and daily use of Truvada as oral pre-exposure prophylaxis (PrEP).   More info…